The compound has been evaluated in two
Phase I clinical trials, and a third Phase I
randomized controlled trial, with a secondary objective of evaluating the effect of treatment on urishiol sensitivity, is due to be completed in December 2022.[7]
^
abUS patent 10322103, Elsohly M, Gul M, Ashfaq MK, "Compositions for prevention/prophylactic treatment of poison ivy dermatitis", issued 18 June 2019, assigned to University of Mississippi
^Kim Y, Flamm A, ElSohly MA, Kaplan DH, Hage RJ, Hamann CP, Marks JG (2019). "Poison Ivy, Oak, and Sumac Dermatitis: What Is Known and What Is New?". Dermatitis. 30 (3): 183–190.
doi:
10.1097/DER.0000000000000472.
PMID31045932.
S2CID143423493.
This article needs additional or more specific
categories. Please
help out by
adding categories to it so that it can be listed with similar articles.(July 2022)